妊娠期补充维生素D:随机试验系统综述的证据现状
该系统综述与Meta分析纳入43项随机对照试验(8406名参与者),评估产前补充维生素D对11项母亲结局和27项新生儿/婴儿结局的影响。维生素D提高母体/脐血25-羟基维生素D浓度,但剂量反应效应弱;母亲临床结局很少被评估或报告,现有数据未提供获益证据。维生素D使平均出生体重增加58.33 g(95%CI 18.88至97.78 g;37项比较),并降低小于胎龄儿出生风险(RR 0.60,95%CI 0.40至0.90;7项比较),但敏感性和亚组分析中结果不稳健;对早产无影响(RR 1.0,95%CI 0.77至1.30;15项比较);有强证据表明产前维生素D降低3岁前后代喘息风险(RR 0.81,95%CI 0.67至0.98;2项比较)。仅8/43项试验(19%)总体低偏倚风险,35项计划/正在进行的RCT可额外贡献12530名参与者。
要点
- 43项试验(8406名参与者)中仅8项(19%)总体低偏倚风险,中位样本量133人,多数试验样本小、质量低。
- 维生素D使平均出生体重增加58.33 g(95%CI 18.88至97.78 g;37项比较),但敏感性和亚组分析中不稳健。
- 维生素D降低小于胎龄儿出生风险(RR 0.60,95%CI 0.40至0.90;7项比较),但敏感性和亚组分析中不稳健。
- 产前维生素D降低3岁前后代喘息风险(RR 0.81,95%CI 0.67至0.98;2项比较),为强证据。
- 对早产无影响(RR 1.0,95%CI 0.77至1.30;15项比较);母亲临床结局很少被评估或报告,现有数据未提供获益证据。
适用人群与场景
- 纳入标准:产前维生素D补充的随机对照试验,对照组给予安慰剂、无维生素D或维生素D≤600 IU/天(或等效剂量),且发表于同行评议期刊。
- Meta分析纳入43项试验,共8406名参与者,中位样本量133人。
研究设计与关键结果
- 研究类型:随机对照试验的系统综述与Meta分析,并系统检索注册但未发表的试验;检索至2017年9月。
- 43项试验(8406名参与者)纳入Meta分析;中位样本量133人;仅8/43项试验(19%)总体低偏倚风险。
- 维生素D提高母体/脐血25-羟基维生素D浓度,但剂量反应效应弱;母亲临床结局很少被评估或报告,现有数据未提供获益证据。
- 维生素D使平均出生体重增加58.33 g(95%CI 18.88至97.78 g;37项比较),但敏感性和亚组分析中不稳健。
- 维生素D降低小于胎龄儿出生风险(RR 0.60,95%CI 0.40至0.90;7项比较),但敏感性和亚组分析中不稳健。
- 对早产无影响(RR 1.0,95%CI 0.77至1.30;15项比较)。
- 产前维生素D降低3岁前后代喘息风险(RR 0.81,95%CI 0.67至0.98;2项比较),为强证据。
- 多数结局的Meta分析仅纳入少数试验的数据;35项计划/正在进行的RCT可额外贡献12530名参与者。
证据类型、等级与局限
- 证据类型:随机对照试验的系统综述与Meta分析。
- 仅8/43项试验(19%)总体低偏倚风险;多数试验样本小、质量低。
- 局限:大多数产前维生素D试验样本小且质量低;母亲临床结局很少被评估或报告;多数结局的Meta分析仅纳入少数试验;出生体重和小于胎龄儿的发现在敏感性和亚组分析中不稳健;现有证据似乎不足以指导临床或政策推荐。
对床旁实践的改变
- 现有证据似乎不足以指导临床或政策推荐。
- 作者认为未来试验应设计并把握功效以检验临床终点,包括妊娠相关母亲状况(如子痫前期)、婴儿生长和呼吸结局。
指南或共识出处
- PROSPERO CRD42016051292
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Objectives To estimate the effects of vitamin D supplementation during pregnancy on 11 maternal and 27 neonatal/infant outcomes; to determine frequencies at which trial outcome data were missing, unreported, or inconsistently reported; and to project the potential contributions of registered ongoing or planned trials.Design Systematic review and meta-analysis of randomised controlled trials; systematic review of registered but unpublished trials.Data sources Medline, Embase, PubMed, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials from inception to September 2017; manual searches of reference lists of systematic reviews identified in the electronic search; and online trial registries for unpublished, ongoing, or planned trials.Eligibility criteria for study selection Trials of prenatal vitamin D supplementation with randomised allocation and control groups administered placebo, no vitamin D, or vitamin D ≤600 IU/day (or its equivalent), and published in a peer reviewed journal.Results 43 trials (8406 participants) were eligible for meta-analyses. Median sample size was 133 participants. Vitamin D increased maternal/cord serum concentration of 25-hydroxyvitamin D, but the dose-response effect was weak. Maternal clinical outcomes were rarely ascertained or reported, but available data did not provide evidence of benefits. Overall, vitamin D increased mean birth weight of 58.33 g (95% confidence interval 18.88 g to 97.78 g; 37 comparisons) and reduced the risk of small for gestational age births (risk ratio 0.60, 95% confidence interval 0.40 to 0.90; seven comparisons), but findings were not robust in sensitivity and subgroup analyses. There was no effect on preterm birth (1.0, 0.77 to 1.30; 15 comparisons). There was strong evidence that prenatal vitamin D reduced the risk of offspring wheeze by age 3 years (0.81, 0.67 to 0.98; two comparisons). For most outcomes, meta-analyses included data from a minority of trials. Only eight of 43 trials (19%) had an overall low risk of bias. Thirty five planned/ongoing randomised controlled trials could contribute 12 530 additional participants to future reviews.Conclusions Most trials on prenatal vitamin D published by September 2017 were small and of low quality. The evidence to date seems insufficient to guide clinical or policy recommendations. Future trials should be designed and powered to examine clinical endpoints, including maternal conditions related to pregnancy (such as pre-eclampsia), infant growth, and respiratory outcomes.Systematic review registration PROSPERO CRD42016051292.
参考来源
- Roth DE, Leung M, Mesfin E, et al. Vitamin D supplementation during pregnancy: state of the evidence from a systematic review of randomised trials. BMJ. 2017. PMID: 29187358. doi:10.1136/bmj.j5237
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。